Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
Scholarship and Professional Work – COPHS
Part of the Medicine and Health Sciences Commons
Part of the Medicine and Health Sciences Commons